Acquired perforating dermatosis
ICD-10 L87.0 · ICD-11 EE70.0

Acquired Perforating Dermatosis Developing During Kinase Inhibitor Therapy

This page addresses a specific clinical scenario: perforating folliculitis arising in a patient currently receiving a molecular-targeted drug (kinase inhibitor), where a causal relationship between the drug and the skin finding is strongly suspected.

Perforating folliculitis developing during molecular-targeted drug (kinase inhibitor) treatment. The literature documents numerous cases associating this dermatologic presentation with this drug class when a causal link is strongly suspected.

When a causal relationship is strongly suspected, management centres on the molecular-targeted drug (kinase inhibitor) currently in use. The structured protocol outlines the recommended course of action for this situation.

Complete clinical decision steps available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/1346-8138.15647

There are many articles indicating that perforating folliculitis might have occurred during the use of molecular-targeted drugs (kinase inhibitors).

In cases where a causal relationship is strongly suspected, we suggest discontinuing the molecular-targeted drug (kinase inhibitor) and consider changing to another drug.

View source ↗